Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial

Hcv Genotype 1 ◽

Chronic Hcv

Faculty Opinions recommendation of Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718438656.793496148 ◽

2014 ◽

Cited By ~ 1

Author(s):

Philip Rosenthal

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(14)60538-9 ◽

2014 ◽

Vol 384 (9941) ◽

pp. 414-426 ◽

Cited By ~ 267

Author(s):

Michael Manns ◽

Patrick Marcellin ◽

Fred Poordad ◽

Evaldo Stanislau Affonso de Araujo ◽

Maria Buti ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

10.1016/s0168-8278(13)61415-4 ◽

2013 ◽

Vol 58 ◽

pp. S569-S570 ◽

Cited By ~ 26

Author(s):

P. Ferenci ◽

T. Asselah ◽

G.R. Foster ◽

S. Zeuzem ◽

C. Sarrazin ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Genotype 1 ◽

Double Blind ◽

Phase Iii Trial ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

Chronic Hcv

Faculty Opinions recommendation of Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718438655.793496147 ◽

2014 ◽

Cited By ~ 1

Author(s):

Philip Rosenthal

Keyword(s):

Controlled Trial ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3 ◽

Double Blind ◽

Treatment Naïve ◽

Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)

Gastroenterology ◽

10.1016/s0016-5085(14)63540-x ◽

2014 ◽

Vol 146 (5) ◽

pp. S-974 ◽

Cited By ~ 4

Author(s):

Donald M. Jensen ◽

Graham Foster ◽

Peter Ferenci ◽

Curtis Cooper ◽

Douglas T. Dieterich ◽

...

Keyword(s):

Pegylated Interferon ◽

Pooled Analysis ◽

Interferon Alfa ◽

Phase Iii ◽

Genotype 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Trials ◽

Treatment Naïve ◽

Faculty Opinions recommendation of Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718438655.793499231 ◽

2014 ◽

Author(s):

Vincent Emery

Keyword(s):

Controlled Trial ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3 ◽

Double Blind ◽

Treatment Naïve ◽

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(14)60494-3 ◽

2014 ◽

Vol 384 (9941) ◽

pp. 403-413 ◽

Cited By ~ 329

Author(s):

Ira M Jacobson ◽

Gregory J Dore ◽

Graham R Foster ◽

Michael W Fried ◽

Monica Radu ◽

...

Keyword(s):

Controlled Trial ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3 ◽

Double Blind ◽

Treatment Naïve ◽

271 EXTENDED TREATMENT OF TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1-INFECTION AND SLOW RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN: A META-ANALYSIS

10.1016/s0168-8278(10)60273-5 ◽

2010 ◽

Vol 52 ◽

pp. S114

Author(s):

C.M. Lange ◽

H. Farnik ◽

C. Sarrazin ◽

B. Kronenberger ◽

S. Zeuzem ◽

...

Keyword(s):

Chronic Hepatitis ◽

Meta Analysis ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Slow Response ◽

Treatment Naïve ◽

Hcv Genotype 1

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

10.1016/s0168-8278(09)61054-0 ◽

2009 ◽

Vol 50 ◽

pp. S382-S383 ◽

Cited By ~ 32

Author(s):

I. Jacobson ◽

P. Pockros ◽

J. Lalezari ◽

E. Lawitz ◽

M. Rodriguez-Torres ◽

...

Keyword(s):

Antiviral Activity ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

10.1016/s0168-8278(13)60068-9 ◽

2013 ◽

Vol 58 ◽

pp. S30 ◽

Cited By ~ 9

Author(s):

M. Manns ◽

J.M. Vierling ◽

B.R. Bacon ◽

P. Marcellin ◽

L. Caro ◽

...

Keyword(s):

Sustained Viral Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

Viral Response ◽

Treatment Naïve ◽

Cirrhotic Patients ◽

Hcv Genotype 1